共 106 条
[1]
Cui L(2022)Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis Arch Osteoporos 17 74-1321
[2]
Xia W(2018)Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review Arch Osteoporos 13 34-612
[3]
Yu C(2013)Eldecalcitol for the treatment of osteoporosis Clin Interv Aging 8 1313-517
[4]
Dong S(2011)A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures–a randomized, active comparator, double-blind study Bone 49 605-97
[5]
Pei Y(2016)Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials Drug Des Devel Ther 10 509-1636
[6]
Fujiwara S(2019)Hypercalcemia and acute kidney injury induced by eldecalcitol in patients with osteoporosis: a case series of 32 patients at a single facility Ren Fail 41 88-463
[7]
Miyauchi A(2022)Hypercalcemia: a review JAMA 328 1624-144
[8]
Hamaya E(2017)The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report J Bone Miner Metab 35 456-528
[9]
Nicholls RJ(2023)Risk of parkinsonism and related movement disorders with gabapentinoids or tramadol: A case-crossover study Pharmacotherapy 43 136-548
[10]
Weston A(2022)Clinical epidemiology and pharmacoepidemiology studies with real-world databases Proceedings of the Japan Academy, Series B 98 517-526